Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007

Pediatric Blood and Cancer

Volumn 54, Issue 7, 2010, Pages 952-958

  Schrey, Dominik ^a   Borghorst, Stephan ^a,b   Lanvers Kaminsky, Claudia ^a   Hempel, Georg ^a,b   Gerß, Joachim ^b   Möricke, Anja ^c   Schrappe, Martin ^c   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ALL BFM; Asparaginase; Childhood leukaemia; Therapeutic drug monitoring; Treatment

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL;

ADOLESCENT; ADULT; ARTICLE; CHILD; DOSE RESPONSE; DRUG MONITORING; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PECTOBACTERIUM CHRYSANTHEMI; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG HYPERSENSITIVITY; DRUG MONITORING; ESCHERICHIA COLI; FEMALE; HUMANS; INFANT; MALE; PECTOBACTERIUM CHRYSANTHEMI; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77951706358     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22417     Document Type: Article

References (31)

1. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383. (Pubitemid 12143059)
2. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
3. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970;25:253-278.
4. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
5. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
6. Wang B, RellingMV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003;17: 1583-1588. (Pubitemid 36992159)
7. Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558. (Pubitemid 12201374)
8. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14:2205-2222.
9. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000;95:3310-3322. (Pubitemid 30428458)
10. Lanvers C, Pinheiro JPV, Hempel G, et al. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309: 117-126.
11. EMEA. http://www.ich.org/LOB/media/MEDIA487.pdf. 2009.
12. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91: 24-31. (Pubitemid 43235382)
13. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
14. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: Results from a single agent window study. Leukemia 2008;22: 1665-1679.
15. Zalewska-Szewczyk B, AndrzejewskiW, Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:600-602. (Pubitemid 39313961)
16. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-1532.
17. Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794-799. (Pubitemid 32953734)
18. Vieira Pinheiro JP, Muller HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001;113:115-119. (Pubitemid 32423311)
19. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-1533.
20. Billett AL, Carls A, Gelber RD, et al. Allergic reactions to erwinia asparaginase in children with acute lymphoblastic-leukemia who had previous allergic reactions to Escherichia-coli asparaginase. Cancer 1992;70:201-206.
21. Nowak-Gottl U, Werber G, Ziemann D, et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996;81:127-131. (Pubitemid 126614413)
22. Sutor AH, Niemeyer C, Sauter S, et al. Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols. Klin Padiatr 1992;204:264-273.
23. Boos J. Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Ther 1997;35:96-98. (Pubitemid 27129612)
24. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550. (Pubitemid 26279122)
25. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681. (Pubitemid 27115859)
26. Avramis VI, Holcenberg JS, Ettinger AG, et al. Failure of asparagine (ASN) depletion, not inadequate asparaginase (ASNase) activity, predicts relapse in standard risk (SR) childhood acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) report. Blood 2007;110:181A.
27. Douer D,Watkins K, Mark L, et al.Adose intensified pediatric-like regimen using multiple doses of intravenous pegylated asparaginase in adults with newly diagnosed acute lymphoblastic leukemia. Blood 2007;110:831A.
28. Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-Lasparaginase and anti metabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia - A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2007;29:369-375. (Pubitemid 46884218)
29. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: Results from a single agent window study. Leukemia 2008;22: 1665-1679.
30. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313-320. (Pubitemid 29083340)
31. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;54:199-205.